Improving the use of hydroxyurea for sickle cell disease in Nigeria
mAnaging siCkle CELl disease through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE)
This study is working to help more people with sickle cell disease in Nigeria get the medicine hydroxyurea, which can really improve their health and reduce serious problems, by making it easier for doctors to prescribe and manage the treatment.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10907044 on NIH RePORTER |
What this research studies
This research focuses on increasing the adoption of hydroxyurea (HU) treatment for sickle cell disease (SCD) in Nigeria, where many patients currently lack access to effective care. The project aims to address barriers that prevent healthcare providers from prescribing HU, which has been shown to reduce complications and mortality associated with SCD. By implementing a structured approach that includes screening, treatment initiation, and ongoing management, the research seeks to enhance patient outcomes through better healthcare practices. The study will utilize evidence-based guidelines and algorithms to facilitate the adoption of HU in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with sickle cell disease living in Nigeria.
Not a fit: Patients with sickle cell disease who are already receiving effective treatment or those living outside Nigeria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the health and quality of life for patients with sickle cell disease in Nigeria by increasing access to effective treatment.
How similar studies have performed: Previous research has demonstrated success in similar approaches to increasing treatment adoption for sickle cell disease in other regions, indicating potential for positive outcomes in this study.
Where this research is happening
New York, United States
- New York University — New York, United States (Active)
Researchers
- Principal investigator: Peprah, Emmanuel K — New York University
- Study coordinator: Peprah, Emmanuel K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.